Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#3565 Grade 3 neuroendocrine neoplasms – Real life experience and prognostic biomarkers

Introduction: Grade 3 neuroendocrine neoplasms (G3 NEN) are a heterogeneous group, including well differentiated tumors (NET) and poorly differentiated carcinomas (NEC), whose identification can be challenging. Accessible prognostic tools are needed to individualize treatment. Data suggests neutrophil/lymphocyte ratios (NLR) and systemic inflammatory index (SII) have prognostic value in NEN.

Conference:

Presenting Author: Rebordão Pires M

Authors: Rebordão Pires M, Monteiro J, Amorim Costa C, Caetano A, Elvas A,

Keywords: Grade 3 neuroendocrine neoplasm, NEC, NET, Neutrophil to lymphocyte ratio, Systemic Inflammatory Index, Ki67, Prognostic biomarker,

#3226 Immunohistochemical staining with neuroendocrine markers is essential in the diagnosis of neuroendocrine neoplasms of the esophagogastric junction

Introduction: Neuroendocrine neoplasms (NENs) of the esophagogastric junction (EGJ) are uncommon and the classification of these tumors has been revised several times. Since 2016, at the Department of Pathology, Rigshospitalet, Denmark, all adenocarcinomas (ACs) and poorly differentiated carcinomas of the EGJ have been stained routinely with the neuroendocrine markers, Synaptophysin and Chromogranin A, in order to detect a possible neuroendocrine component.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Jepsen D

Authors: Jepsen D, Fiehn A, Garbyal R, Engel U, Holm J,

Keywords: neuroendocrine neoplasm, neuroendocrine carcinoma, mixed neuroendocrine non-neuroendocrine neoplasm, esophagogastric junction, Synaptophysin, Chromogranin A,

#2865 Can the Efficacy of Etoposide-Platinum Chemotherapy Be Predicted by p53/pRb Status in Grade 3 Neuroendocrine Neoplasms (G3 NEN)?

Introduction: Etoposide-platinum (EP) chemotherapy has long stood as the reference treatment of grade 3 neuroendocrine neoplasms (G3 NEN). However, G3 NEN are heterogeneous, including well differentiated tumours (NET) and poorly differentiated carcinomas of large (LCNEC) or small (SCNEC) cell type, whose identification can be challenging and response to EP be very variable, usually low in NET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Lacombe C, De Rycke O, Chen R, Colnot N, Hentic O,

Keywords: grade 3, chemotherapy, biomarkers, etoposide-platinum, pRb, p53,

#2133 Clinicopathological Features of the High Grade Pancreatic Neuroendocrine Neoplasms

Introduction: The high grade pancreatic neuroendocrine neoplasms (PanNENs) include well-differentiated tumors (WD-NETs) with elevated proliferation and poorly differentiated carcinomas (PD-NECs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Delektorskaya V, Solovieva O, Koslov N, Patyutko Y,

Keywords: neuroendocrine, pancreas, neoplasm, grade, survival,

#1911 Histological Differentiation Provides Useful, Additive and Independent Prognostic Information to Proliferation Index in G2 and G3 Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)

Introduction: The WHO 2010 classification has provided a valuable tool to stratify NEN prognosis based on an objective measure, the proliferation index. However, morphology and, in particular, tumor differentiation, is emerging again as a relevant feature that should not be dismissed due to its important clinical implications.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: García Carbonero R

Authors: Sánchez Cánovas M, Nuñez B, Benavent M, Teulé A, Segura A,

Keywords: WHO 2010 classification,